Spotlight on Allergy & Immunology
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Lupus
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Allergy & Immunology Presentations
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Lupus
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Improving the Delivery of Immunotherapy for Peanut Allergy Management – Rapid Response From Lisbon
StartActivity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
HIV in Aging Patients eHealth Source™ - HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
StartActivity Details
Expires: July 15, 2020
Jointly Provided by
Target Audience
This activity is intended for infectious disease and human immunodeficiency virus (HIV) specialist physicians and other clinicians involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review the role of inflammation in the comorbidities commonly associated with HIV in aging patients
- Tailor screening and treatment for common age-related HIV comorbidities, such as decreased bone mineral density and renal disease
- Address CV risk in aging patients with HIV through selection of appropriate ART regimens and incorporation of recommended therapies to prevent CVD
- Utilize knowledge of virus-related cancers to appropriately screen patients with HIV
- Implement screening and appropriate treatment strategies for depression and HAND in aging patients with HIV
Activity Description
This HIV eHealth comprises 5 text-based chapters discussing common comorbidities seen in aging patients with HIV and supplemental videos that provide more detailed explanations of important concepts in HIV and aging as well as examples of best practices.
Statement of Educational Need
People with HIV (PWH) have a life expectancy that is only slightly shorter than that of the general population. In the United States, more than half of the 1.3 million PWH are older than 50 years—and the average age is rising.1 As PWH age, the risk of comorbidities and multimorbidity increases.2 The age-related multimorbidity seen in PWH is believed to be caused by HIV-associated chronic inflammation, immune dysregulation, and immune cell senescence.1 Comorbidity burden in aging PWH has a substantial negative effect on quality of life. Comorbidities of particular concern are cardiovascular disease, decreased bone mineral density, cancer, neurocognitive impairment and depression, and renal disease. These comorbidities may be influenced both by antiretroviral therapy (ART) and by HIV itself. There is a need for clinicians to better understand these comorbidities and form multidisciplinary teams to appropriately care for their aging patients with HIV. This HIV eHealth program includes epidemiology, pathophysiology, diagnosis, and management strategies for common comorbidities seen in aging PWH, including effect of ART on comorbidities and how each comorbidity may influence ART selection.
References
- Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61-68.
- Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.
Agenda
Introduction
Chapter 1: Inflammation and Cardiovascular Disease Risk in HIV
Chapter 2: Bone Density and Osteoporosis Screening and Management
Chapter 3: HIV and Related Cancers
Chapter 4: Neurocognitive Impairment and Depression in HIV
Chapter 5: Renal Disease in Aging Patients With HIV
Faculty
Adult Cardiologist
Director, HIV Cardiometabolic Risk Clinic
University Hospitals Harrington Heart & Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio
Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases and HIV Program
Brigham and Women’s Hospital
Boston, Massachusetts
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Chris Longenecker, MD
Grant/Research Support: Gilead Sciences, Inc.
Paul E. Sax, MD
Consultant/Independent Contractor: AbbVie Inc., Bristol-Myers
Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Janssen
Pharmaceuticals, Inc., Merck & Co., Inc.
Grant/ Research Support: Bristol-Myers Squibb, Gilead Sciences,
Inc., GlaxoSmithKline/ViiV Healthcare, Merck & Co., Inc.
The following planners and managers
reported no financial relationships or relationships to products or devices
they or their spouses/life partners have with commercial interests related to
the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley
Cann, Gena Dolson, MS, Celeste Collazo, MD, Jim Kappler, PhD
Physicians Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physicians Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions about the Activity
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
Expires: July 15, 2020
Jointly Provided by
Target Audience
This activity is intended for infectious disease and human immunodeficiency virus (HIV) specialist physicians and other clinicians involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review the role of inflammation in the comorbidities commonly associated with HIV in aging patients
- Tailor screening and treatment for common age-related HIV comorbidities, such as decreased bone mineral density and renal disease
- Address CV risk in aging patients with HIV through selection of appropriate ART regimens and incorporation of recommended therapies to prevent CVD
- Utilize knowledge of virus-related cancers to appropriately screen patients with HIV
- Implement screening and appropriate treatment strategies for depression and HAND in aging patients with HIV
Activity Description
This HIV eHealth comprises 5 text-based chapters discussing common comorbidities seen in aging patients with HIV and supplemental videos that provide more detailed explanations of important concepts in HIV and aging as well as examples of best practices.
Statement of Educational Need
People with HIV (PWH) have a life expectancy that is only slightly shorter than that of the general population. In the United States, more than half of the 1.3 million PWH are older than 50 years—and the average age is rising.1 As PWH age, the risk of comorbidities and multimorbidity increases.2 The age-related multimorbidity seen in PWH is believed to be caused by HIV-associated chronic inflammation, immune dysregulation, and immune cell senescence.1 Comorbidity burden in aging PWH has a substantial negative effect on quality of life. Comorbidities of particular concern are cardiovascular disease, decreased bone mineral density, cancer, neurocognitive impairment and depression, and renal disease. These comorbidities may be influenced both by antiretroviral therapy (ART) and by HIV itself. There is a need for clinicians to better understand these comorbidities and form multidisciplinary teams to appropriately care for their aging patients with HIV. This HIV eHealth program includes epidemiology, pathophysiology, diagnosis, and management strategies for common comorbidities seen in aging PWH, including effect of ART on comorbidities and how each comorbidity may influence ART selection.
References
- Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61-68.
- Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.
Agenda
Introduction
Chapter 1: Inflammation and Cardiovascular Disease Risk in HIV
Chapter 2: Bone Density and Osteoporosis Screening and Management
Chapter 3: HIV and Related Cancers
Chapter 4: Neurocognitive Impairment and Depression in HIV
Chapter 5: Renal Disease in Aging Patients With HIV
Faculty
Adult Cardiologist
Director, HIV Cardiometabolic Risk Clinic
University Hospitals Harrington Heart & Vascular Institute
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio
Professor of Medicine
Harvard Medical School
Clinical Director, Division of Infectious Diseases and HIV Program
Brigham and Women’s Hospital
Boston, Massachusetts
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Chris Longenecker, MD
Grant/Research Support: Gilead Sciences, Inc.
Paul E. Sax, MD
Consultant/Independent Contractor: AbbVie Inc., Bristol-Myers
Squibb, Gilead Sciences, Inc., GlaxoSmithKline/ViiV Healthcare, Janssen
Pharmaceuticals, Inc., Merck & Co., Inc.
Grant/ Research Support: Bristol-Myers Squibb, Gilead Sciences,
Inc., GlaxoSmithKline/ViiV Healthcare, Merck & Co., Inc.
The following planners and managers
reported no financial relationships or relationships to products or devices
they or their spouses/life partners have with commercial interests related to
the content of this CME activity:
Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley
Cann, Gena Dolson, MS, Celeste Collazo, MD, Jim Kappler, PhD
Physicians Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physicians Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest.
Statement of Commercial Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions about the Activity
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.